Alogliptin monotherapy improves glycemic control in patients with type 2 diabetes
The team at TBT of Ga set me up on their Combination Therapy Program and during my first visit the results were amazing
The authors then treated dorsal root ganglion neurons with exendin-4
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
But after stopping the injections, a common concern sets in: Will the weight come back
Our formula combines follicle-activating peptides with tretinoin for deeper penetration and results that minoxidil alone cant deliver